계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Kyverna Therapeutics
company
About
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $85M
- Industries
- Biotechnology,Life Science,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$85M
Kyverna Therapeutics has raised a total of
$85M
in funding over 2 rounds. Their latest funding was raised on
Jan 26, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 26, 2022 | Series B | $85M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Kyverna Therapeutics is funded by 2 investors.
Intellia Therapeutics
and jVen Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Intellia Therapeutics
|
— | Series B |
jVen Capital
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
